This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Exelixis Announces Presentation Of Updated Phase 1b Data For Cobimetinib (GDC-0973/XL518) In Combination With Vemurafenib At ECC 2013

Safety

The most common adverse events (AEs) regardless of attribution to study treatment in the 128 patients treated to date were: non-acneiform rash (35% [2% ≥ Grade 3] for vemurafenib-progressors; and 89% [13% ≥ Grade 3] for BRAFi-naïve), diarrhea (48% [3%]; 81% [8%]), photosensitivity/sunburn (48% [3%]; 70% [0%])), fatigue (28% [2%]; 67% [10%]), nausea (32% [3%]; 56% [3%]), arthralgia (11% [2%]; 48% [11%]), CPK elevation (15% [2%]; 43% [3%]), fever (14% [0%]; 43% [2%]), peripheral edema (20% [0%]; 41% [0%]), vomiting (19% [2%]; 37% [0%]), and acneiform rash (12% [2%]; 33% [3%]). Selected AEs were: choreoretinopathy (2% [0]; 9% [0%]), cardiomyopathy [0% [0%]; 2% [2%]), and squamous cell carcinoma/keratocanthoma (8% [6%]; 10% [5%]).

Temporary interruptions in vemurafenib, cobimetinib, or the combination of both agents were reported in 20%, 20%, and 19% of the 65 vemurafenib-progressor patients, respectively. Dose reductions were reported in 5% 3%, and 3% of vemurafenib-progressor patients, respectively, and permanent discontinuation was reported for vemurafenib (3%) only. Among the 63 BRAFi-naïve patients, temporary interruptions in vemurafenib, cobimetinib, or the combination of both agents were reported in 67%, 49%, and 46%, and dose reductions were reported in 19%, 16% and 2% of patients, respectively. Permanent discontinuation of cobimetinib was reported for one BRAFi-naïve patient (2%). None of the 128 patients receiving the combination of vemurafenib and cobimetinib discontinued treatment due to an adverse event to date.

About Cobimetinib (GDC-0973/XL518)

Cobimetinib is an inhibitor of MEK, a serine/threonine kinase that is a component of the RAS/RAF/MEK/ERK pathway. This pathway mediates signaling downstream of growth factor receptors, and is prominently activated in a wide variety of human tumors. In preclinical studies, oral dosing of cobimetinib resulted in sustained inhibition of MEK in RAS or BRAF mutant tumor models. Cobimetinib is being developed by Genentech, a member of the Roche Group under a collaboration agreement with Exelixis.

3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs